Literature DB >> 11391481

Homocysteine metabolism in children with Down syndrome: in vitro modulation.

M Pogribna1, S Melnyk, I Pogribny, A Chango, P Yi, S J James.   

Abstract

The gene for cystathionine beta-synthase (CBS) is located on chromosome 21 and is overexpressed in children with Down syndrome (DS), or trisomy 21. The dual purpose of the present study was to evaluate the impact of overexpression of the CBS gene on homocysteine metabolism in children with DS and to determine whether the supplementation of trisomy 21 lymphoblasts in vitro with selected nutrients would shift the genetically induced metabolic imbalance. Plasma samples were obtained from 42 children with karyotypically confirmed full trisomy 21 and from 36 normal siblings (mean age 7.4 years). Metabolites involved in homocysteine metabolism were measured and compared to those of normal siblings used as controls. Lymphocyte DNA methylation status was determined as a functional endpoint. The results indicated that plasma levels of homocysteine, methionine, S-adenosylhomocysteine, and S-adenosylmethionine were all significantly decreased in children with DS and that their lymphocyte DNA was hypermethylated relative to that in normal siblings. Plasma levels of cystathionine and cysteine were significantly increased, consistent with an increase in CBS activity. Plasma glutathione levels were significantly reduced in the children with DS and may reflect an increase in oxidative stress due to the overexpression of the superoxide dismutase gene, also located on chromosome 21. The addition of methionine, folinic acid, methyl-B(12), thymidine, or dimethylglycine to the cultured trisomy 21 lymphoblastoid cells improved the metabolic profile in vitro. The increased activity of CBS in children with DS significantly alters homocysteine metabolism such that the folate-dependent resynthesis of methionine is compromised. The decreased availability of homocysteine promotes the well-established "folate trap," creating a functional folate deficiency that may contribute to the metabolic pathology of this complex genetic disorder.

Entities:  

Mesh:

Substances:

Year:  2001        PMID: 11391481      PMCID: PMC1226051          DOI: 10.1086/321262

Source DB:  PubMed          Journal:  Am J Hum Genet        ISSN: 0002-9297            Impact factor:   11.025


  34 in total

1.  Isolation and initial characterization of a novel zinc finger gene, DNMT3L, on 21q22.3, related to the cytosine-5-methyltransferase 3 gene family.

Authors:  U Aapola; K Kawasaki; H S Scott; J Ollila; M Vihinen; M Heino; A Shintani; K Kawasaki; S Minoshima; K Krohn; S E Antonarakis; N Shimizu; J Kudoh; P Peterson
Journal:  Genomics       Date:  2000-05-01       Impact factor: 5.736

Review 2.  Oxidative stress and neural dysfunction in Down syndrome.

Authors:  R C Iannello; P J Crack; J B de Haan; I Kola
Journal:  J Neural Transm Suppl       Date:  1999

3.  [Amino acids and trisomy 21].

Authors:  J Lejeune; M O Rethoré; M C de Blois; M Peeters; J Naffah; A Megarbane; F Cattaneo; C Mircher; D Rabier; P Parvy
Journal:  Ann Genet       Date:  1992

4.  Leucocyte ultrastructure and folate metabolism in Down's syndrome.

Authors:  G S Gericke; P B Hesseling; S Brink; F C Tiedt
Journal:  S Afr Med J       Date:  1977-03-19

5.  Methotrexate sensitivity in Down's syndrome: a hypothesis.

Authors:  P M Ueland; H Refsum; B Christensen
Journal:  Cancer Chemother Pharmacol       Date:  1990       Impact factor: 3.333

6.  Is absence of atheroma in Down syndrome due to decreased homocysteine levels?

Authors:  B Chadefaux; I Ceballos; M Hamet; M Coude; M Poissonnier; P Kamoun; D Allard
Journal:  Lancet       Date:  1988-09-24       Impact factor: 79.321

7.  A new HPLC method for the simultaneous determination of oxidized and reduced plasma aminothiols using coulometric electrochemical detection.

Authors:  S Melnyk; M Pogribna; I Pogribny; R J Hine; S J James
Journal:  J Nutr Biochem       Date:  1999-08       Impact factor: 6.048

8.  In vivo folic acid supplementation partially corrects in vitro methotrexate toxicity in patients with Down syndrome.

Authors:  M A Peeters; M O Rethore; J Lejeune
Journal:  Br J Haematol       Date:  1995-03       Impact factor: 6.998

9.  Postnatal delay of myelin formation in brains from Down syndrome infants and children.

Authors:  K E Wisniewski; B Schmidt-Sidor
Journal:  Clin Neuropathol       Date:  1989 Mar-Apr       Impact factor: 1.368

10.  Pharmacokinetics of leucovorin metabolites in human plasma as a function of dose administered orally and intravenously.

Authors:  D G Priest; J C Schmitz; M A Bunni; R K Stuart
Journal:  J Natl Cancer Inst       Date:  1991-12-18       Impact factor: 13.506

View more
  66 in total

Review 1.  Cerebrovascular contributions to aging and Alzheimer's disease in Down syndrome.

Authors:  Donna M Wilcock; Frederick A Schmitt; Elizabeth Head
Journal:  Biochim Biophys Acta       Date:  2015-11-26

Review 2.  Nitric oxide and redox mechanisms in the immune response.

Authors:  David A Wink; Harry B Hines; Robert Y S Cheng; Christopher H Switzer; Wilmarie Flores-Santana; Michael P Vitek; Lisa A Ridnour; Carol A Colton
Journal:  J Leukoc Biol       Date:  2011-01-13       Impact factor: 4.962

3.  Maternal nutrition and stage of early pregnancy in beef heifers: impacts on hexose and AA concentrations in maternal and fetal fluids1.

Authors:  Matthew S Crouse; Nathaniel P Greseth; Kyle J McLean; Mellissa R Crosswhite; Nicolas Negrin Pereira; Alison K Ward; Lawrence P Reynolds; Carl R Dahlen; Bryan W Neville; Pawel P Borowicz; Joel S Caton
Journal:  J Anim Sci       Date:  2019-03-01       Impact factor: 3.159

4.  DHFR 19-bp deletion and SHMT C1420T polymorphisms and metabolite concentrations of the folate pathway in individuals with Down syndrome.

Authors:  Cristiani Cortez Mendes; Aline Maria Zanchetta de Aquino Raimundo; Luciana Dutra Oliveira; Bruna Lancia Zampieri; Gustavo Henrique Marucci; Joice Matos Biselli; Eny Maria Goloni-Bertollo; Marcos Nogueira Eberlin; Renato Haddad; Maria Francesca Riccio; Hélio Vannucchi; Valdemir Melechco Carvalho; Érika Cristina Pavarino
Journal:  Genet Test Mol Biomarkers       Date:  2013-02-19

5.  Genetic polymorphisms modulate the folate metabolism of Brazilian individuals with Down syndrome.

Authors:  J M Biselli; B L Zampieri; E M Goloni-Bertollo; R Haddad; M F R Fonseca; M N Eberlin; H Vannucchi; V M Carvalho; E C Pavarino
Journal:  Mol Biol Rep       Date:  2012-08-19       Impact factor: 2.316

6.  DYRK1A, a novel determinant of the methionine-homocysteine cycle in different mouse models overexpressing this Down-syndrome-associated kinase.

Authors:  Christophe Noll; Chris Planque; Clémentine Ripoll; Fayçal Guedj; Anna Diez; Véronique Ducros; Nicole Belin; Arnaud Duchon; Jean-Louis Paul; Anne Badel; Bénédicte de Freminville; Yann Grattau; Henri Bléhaut; Yann Herault; Nathalie Janel; Jean-Maurice Delabar
Journal:  PLoS One       Date:  2009-10-21       Impact factor: 3.240

7.  Plasma amino acids and neopterin in healthy persons with Down's syndrome.

Authors:  A W Coppus; D Fekkes; W M A Verhoeven; S Tuinier; J I M Egger; C M van Duijn
Journal:  J Neural Transm (Vienna)       Date:  2007-03-31       Impact factor: 3.575

8.  A novel mouse model for Down syndrome that harbor a single copy of human artificial chromosome (HAC) carrying a limited number of genes from human chromosome 21.

Authors:  Kenichi Miyamoto; Nobutaka Suzuki; Kosuke Sakai; Shuichi Asakawa; Tsuneko Okazaki; Jun Kudoh; Masashi Ikeno; Nobuyoshi Shimizu
Journal:  Transgenic Res       Date:  2013-11-30       Impact factor: 2.788

9.  Effect of leucovorin (folinic acid) on the developmental quotient of children with Down's syndrome (trisomy 21) and influence of thyroid status.

Authors:  Henri Blehaut; Clotilde Mircher; Aimé Ravel; Martine Conte; Veronique de Portzamparc; Gwendael Poret; Françoise Huon de Kermadec; Marie-Odile Rethore; Franck G Sturtz
Journal:  PLoS One       Date:  2010-01-11       Impact factor: 3.240

10.  A new mouse model for the trisomy of the Abcg1-U2af1 region reveals the complexity of the combinatorial genetic code of down syndrome.

Authors:  Patricia Lopes Pereira; Laetitia Magnol; Ignasi Sahún; Véronique Brault; Arnaud Duchon; Paola Prandini; Agnès Gruart; Jean-Charles Bizot; Bernadette Chadefaux-Vekemans; Samuel Deutsch; Fabrice Trovero; José María Delgado-García; Stylianos E Antonarakis; Mara Dierssen; Yann Herault
Journal:  Hum Mol Genet       Date:  2009-09-26       Impact factor: 6.150

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.